natgillin/translations-raw huggingface dataset:
Process according to any one of claims 1 to 3, wherein said oxidized furan derivative comprises at least one aldehyde group and/or at least one carboxylic acid group. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time, da navedeni oksidirani derivati furana sadržavaju barem jednu aldehidnu skupinu i / ili barem jednu karboksilnu kiselinsku skupinu.
The method for separating the components of an ammunition cartridge (10) according to claim 13, where step b) for extracting the bullet (11) from the cartridge (10) comprises the following steps: 
Postupak rastavljanja komponenti čahure streljiva (10) u skladu s patentnim zahtjevom 10, naznačen time što se korak b) izvlačenja zrna (11) 1z čahure (10) sastoji u sljedećim koracima:
The compound of any one of claims 1-5, wherein 
Tvar iz bilo kojeg od patentnih zahtjeva 1-5, gdje i)
admixing methyl 4-(3-amino-2-fluorobenzyl)piperazine-1-carboxylate and phenyl (6-methylpyridin-3-yl)carbamate in the presence of a trialkylamine base to form omecamtiv mecarbil as a free base; and crystallizing the omecamtiv mecarbil free base in the presence of aqueous hydrochloric acid and an alcohol solvent to form omecamtiv mecarbil dihydrochloride hydrate salt. 
(b) miješanje metil 4-(3-amino-2-fluorobenzil)piperazin-1-karboksilata i fenil (6-metilpiridin-3-il)karbamata u prisutnosti trialkilamin baze kako bi nastao omekamtiv mekarbil kao slobodna baza; i (c) kristaliziranje slobodne baze omekamtiv mekarbila u prisutnosti vodene klorovodične kiseline i alkoholnog otapala kako bi nastala dihidroklorid hidratna sol omekamtiv mekarbila.
Method for building a contig of a genomic region of interest comprising a target nucleotide sequence, comprising, fragmenting a crosslinked DNA, ligating the fragmented cross linked DNA, reversing the crosslinking and determining at least part of the sequences of ligated DNA fragments, comprising a DNA fragment with the target nucleotide sequence, and using the determined sequences to build a contig of the genomic region of interest. 
Postupak građenja kontiga genomskog područja od interesa koje sadrži ciljani nukleotidni slijed, naznačen time što se sastoji u: fragmentiranju umrežene DNA, ligiranju fragmentirane umrežene DNA, razvrgavanju umreženja i određivanju u najmanju ruku dijela sljedova ligiranih fragmenata DNA, koji sadrže fragment DNA s ciljanim nukleotidnim slijedom, te upotrebi određenih sljedova u građenju kontiga genomskog područja od interesa.
said algorithm is a nearest centroid algorithm; or 
(i) navedeni algoritam je najbliži centroidni algoritam; ili
an antisense oligomer comprising a nucleotide sequence of SEQ ID NO: 1 or 2; 
(a) antisensni oligomer koji sadrži nukleotidnu sekvencu SEQ ID NO: 1 ili 2;
A dosage form according to claim 1, which comprises the wax (D) and the wax (D) is at least one natural, semi-synthetic or synthetic wax with a softening point of at least 60° C. 
Oblik davanja lijeka prema jednom od patentnih zahtjeva 1 do 6, naznačen time, da kao vosak (D) sadrži najmanje jedan prirodni, polusintetski ili sintetski vosak s točkom omekšavanja od najmanje 60%C.
an extractor (r1917-L1, r1912-L1) configured to extract the constellation values corresponding to L1 signaling data from the frequency-deinterleaved constellation values corresponding to L1 signaling data and Layer 1 header; 
Sustav vađenja bitova iz među-pohrane (r714-L1), konfiguriran za vađenje bitova sloja 1 odašiljanih podataka iz među-pohrane; i FEC (Forward Error Correction) dekoder (r715-L1) koji je konfiguriran za FEC dekodiranje izvađenih bitova sloja 1 odašiljanih podataka iz među-pohrane.
An anti-FcRn antibody or binding fragment thereof according to claim 5, wherein the polymer is PEG, for example with a molecular weight in the range 5 to 50kDa. 
Anti-FcRn antitijelo ili njegov fragment prema patentnom zahtjevu 5, naznačen time, što je polimer PEG, primjerice s molekularnom masom u rasponu od 5 do 50 kDa.
The peptide according to any one of claims 1 to 4 for use in medicine. 
Farmaceutski sastav za uporabu prema zahtjevu 11, naime kao cjepivo protiv karcinoma.
A compound of formula (I) and their pharmaceutically acceptable salt, solvate or polymorph thereof wherein 
(I) i njegova farmaceutski prihvatljiva sol, solvat ili njihov polimorf naznačen time da
The method for manufacturing the shoe 10 provides, for example, for the manufacture of the lower layer 18 by direct injection in a mold, for the subsequent application of the membrane element 22 in the mold, and for the placement of the breathable element 21. 
Postupak za proizvodnju cipela 10 omogućuje, na primjer, proizvodnju donjeg sloja 18 izravnim prešanjem u kalupu, naknadno postavljanje membranskog elementa 22 u kalup i postavljanje prozračnog elementa 21.
The FGF-18 compound for use according to any of the preceding claims, wherein the FGF-18 compound is selected from the group consisting of: a polypeptide comprising or consisting of the human FGF-18 mature form comprising residues 28-207 of SEQ ID NO:1, or 
Spoj FGF-18 za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time što je spoj FGF-18 odabran iz skupine koju čine: a) - polipeptid koji sadrži ili se sastoji od ljudskog zrelog oblika FGF-18 koji sadrži ostatke 28-207 iz SEQ ID NO:1,ili b) polipeptid koji sadrži ili se sastoji od SEQ ID NO:2.
sending, by the SGW, the special data packet to the source eNB, wherein the special data packet is generated by the SGW; 
pri čemu poseban paket podataka ne sadrži korisničke podatke i poseban paket podataka je generiran pomoću SGW i poslan prema izvorišnom eNB nakon što SGW provede komutaciju puta;
The method of claim 1 wherein the non- biodegradable solids separated comprise at least about 20% of the dry weight of the MSW. The method of claim 1 wherein the non- biodegradable solids separated comprise at least about 20% by dry weight of recyclable materials. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što odvojene bionerazgradljive krutine čine u najmanju ruku otprilike 20 % suhe težine MSW, i/ili što odvojene bionerazgradljive krutine čine u najmanju ruku otprilike 20 % suhe težine obnovljivih materijala.
The forming method according to claim 7, comprising taking process air flowing out of the forming chamber and introducing it into the forming mandrel, so as to cool the forming mandrel. 
Postupak oblikovanja prema zahtjevu 14 kada ovisi, izravno ili neizravno, o zahtjevu 12, naznačen time da sadrži uzimanje zraka za postupak koji istječe iz komore za oblikovanje (1) i njegovo uvođenje u rog za oblikovanje (13), kako bi se ohladio rog za oblikovanje (13).
wherein the distal end of the male connection member includes at least one projection that is configured to rupture the peripheral region of the septum when the male connection member is received in the female connection member to form a connection so that a portion of the central region is permanently separated from the peripheral region and another portion of the central region remains attached to the peripheral region when ruptured; 
Sustav prema bilo kojem prethodnom zahtjevu, naznačen time da ženski spojni element (1010) definira utor ključanice (1011) za primanje ključa (1211) koji se proteže od distalnog dijela muškog spojnog elementa (1200), tako da ženski spojni element može primiti samo distalni dio muškog spojnog elementa da tvori spoj kada je ključ poravnat s utorom ključanice.
Single-portion package, system and process for preparing liquid products based upon said single-portion packages 
JEDNODIJELNO PAKIRANJE, SUSTAV I POSTUPAK PRIPREME TEKUĆIH PROIZVODA TEMELJEN NA JEDNODIJELNIM PAKIRANJIMA
Support according to claim 1, characterized in that the first and second connection segments are arranged perpendicularly to a contact surface of the wall fastening segment, which surface is designed for mounting to the building wall. 
Konzola (100) prema barem jednom od prethodnih patentnih zahtjeva, naznačena time, da je konzola (10, 100) oblikovana kao dvoslojni lim u području plohe nalijeganja (20) sekcije za pričvršćivanje stijenke (14).
A compound according to claim 1, or a pharmaceutically acceptable salt thereof, for use in treating a genetic disease caused by mutations in Wnt signaling components, wherein the genetic disease is selected from: polyposis coli, osteoporosis-pseudoglioma syndrome, familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia syndrome, Müllerian-duct regression and virilization, SERKAL syndrome, diabetes mellitus type 2, Fuhrmann syndrome, Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome, odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation, caudal duplication syndrome, tooth agenesis, Wilms tumor, skeletal dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile X syndrome, ICF syndrome, Angelman syndrome, Prader-Willi syndrome, Beckwith-Wiedemann Syndrome and Rett syndrome. 
Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen time da je za upotrebu za liječenje genetske bolesti uzrokovane mutacijama u Wnt signalnim komponentama, pri čemu je genetska bolest odabrana iz skupa koji čine: polipoza coli, osteoporoza-pseudoglioma sindrom, obiteljska eksudativna vitreoretinopatija, retinalna angiogeneza, rana koronarna bolest, sindrom tetra-amelia, regresija i virilizacija Miillerovih kanala, SERKAL sindrom, dijabetes melitus tipa 2, Fuhrmannov sindrom, Al-Awadi/Raas-Rothschild/Schinzelov fokomelija sindrom, odonto-oniho-dermalna displazija, pretilost, malformacija razdvojena ruka/stopalo, sindrom kaudalnog dupliciranja, ageneza zuba, Wilmsov tumor, skeletna displazija, fokalna dermalna hipoplazija, autosomna recesivna anonihija, defekti neuralne cijevi, alfa-talasemija (ATRX) sindrom, sindrom lomljivog kromosoma X, ICF sindrom, Angelmanov sindrom, Prader-Willijev sindrom, Beckwith-Wiedemannov sindrom i Rettov sindrom.
RE and RF are each independently C1-C6 alkyl, optionally substituted by a group C1-C3 alkyl, -ORG, -CN or halo; alternatively, RE and RF may form together with the nitrogen atom to which they are attached a 5-11- membered saturated monocyclic or bicyclic heterocyclic ring system which is optionally substituted by one or more groups -ORG, -CN, halo, C1-C6 alkyl or C3-C7 cycloalkyl, such C1-C6 alkyl and C3-C7 cycloalkyl being optionally substituted by a group C1-C3 alkyl, C3-C7cycloalkyl, -ORG, -CN or halo; and which 5-11-membered saturated monocyclic or bicyclic heterocyclic ring optionally contains a further heteroatom which is oxygen or nitrogen, said nitrogen atom optionally substituted by C1-C6 alkyl or C3-C6 cycloalkyl, wherein any of such C1-C6 alkyl or C3-C6 cycloalkyl may be optionally substituted by a group C1-C6 alkyl or C3-C7 cycloalkyl; 
RE i RF svaki neovinso jest C1–C6alkil, koji može biti supstituiran skupinom C1–C3alkil, –ORG, –CN ili halogen; alternativno, RE i RF mogu zajedno s dušikovim atomom za koji su vezani tvoriti zasićeni 5–11-člani monociklički ili biciklički heterociklički sustav prstena koji može biti supstituiran sljedećim skupinama: –ORG, –CN, halogen, C1–C6alkil ili C3–C7 cikloalkil, a takav C1–C6alkil i C3–C7cikloalkil može biti supstituiran sljedećom skupinom: C1–C3alkil, C3–C7cikloalkil, –ORG, –CN ili halogen; a koji 5–11–člani zasićeni monociklički ili biciklički heterociklički prsten može sadržavati daljnji heteroatom koji je kisik ili dušik, a rečeni dušikov atom može biti supstituiran C1–C6alkilom ili C3–C6cikloalkilom, pri čemu bilo koji takav C1–C6alkil ili C3–C6cikloalkil može biti supstituiran skupinom C1–C6alkil ili C3–C7cikloalkil; RG is vodik, –CH3 ili –C2H5;
The release rate of the drug is governed by the Fick's Law of Diffusion as applied to a cylindrically shaped reservoir device (cartridge). 
Uređaj za oslobađanje lijeka prema patentnom zahtjevu 1, naznačen time što je najmanje jedan aktivni sastojak histrelin acetat.
The compound according to claim 16, wherein RD1 and RD2, taken together with phenyl containing carbon atoms 3″ and 4″, is 
Spoj prema zahtjevu 10, naznačen time da R"' i R"", uzeti zajedno s fenilom koji sadrži ugljikove atome 3" i 4", je
The antibody for use according to claim 3, in which the antibody is a monoclonal, chimeric or humanized antibody, or is a fragment of an antibody, said fragment specifically binding to the protein according to claim 3. 
Farmaceutski pripravak radi primjene sukladno bilo kojem od zahtjeva 1 do 3, pri čemu je protutijelo monoklonalno, kimerno ili humanizirano protutijelo ili fragment koji veže antigen protutijela.
A structure according to claim 1, characterized in that it comprises at least one passage region (80) from one side of the sound-absorbing structure to the other, the said region being located in one of the containment sections (2, 4, 6, 8, 10, 12). A structure according to claim 1, characterized in that it also comprises means (60, 62) for anchoring the structure to the ground, which means are connected to the frame means (20). 
Konstrukcija u skladu s patentnim zahtjevom 1, naznačena time, da ona sadrži barem jedan dio (80) za prolaz od jedne strane zvučno-apsorbirajuće konstrukcije na drugu, a navedeni dio je smješten u jednoj od ograđenih sekcija Konstrukcija u skladu s patentnim zahtjevom 1, naznačena time, da ona također sadrži sredstva (60, 62) za sidrenje konstrukcije u tlo, koja su sredstva povezana sa sredstvima okvira (20).
An immunoconjugate according to claim 22 or 23, wherein said growth inhibitory agent is selected from the group consisting of chemotherapeutic agents, enzymes, antibiotics, and toxins such as small molecule toxins or enzymatically active toxins, taxoids, vincas, taxanes, maytansinoid or maytansinoid analogs, tomaymycin or pyrrolobenzodiazepine derivatives, cryptophycin derivatives, leptomycin derivatives, auristatin or dolastatin analogs, prodrugs, topoisomerase II inhibitors, DNA alkylating agenst, anti-tubulin agents, and CC-1065 or CC-1065 analogs. 
Imunokonjugat prema patentnom zahtjevu 7 ili 8, naznačen time što je navedeno sredstvo za inhibiciju rasta odabrano iz skupine koju čine kemoterapeutska sredstva, enzimi, antibiotici, i toksini kao što su toksini malih molekula ili enzimatski aktivni toksini, taksoidi, vinka, taksani, majtanzinoid ili analozi majtanzinoida, tomamicin ili derivati pirolobenzodiazepina, derivati kriptoficina, derivati leptomicina, analozi auristatina ili dolastatina, predlijekovi, inhibitori topoizomeraze II, DNA alkilirajuća sredstva, anti-tubulinska sredstva, te analozi CC-1065 ili CC-1065.
There is also therefore provided a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of allergic diseases and other inflammatory conditions, infectious diseases, and cancer. 
R? je vodik, Ci .galkil ili C3;cikloalkilCo galkil; ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju alergijskih bolesti i drugih upalnih stanja, primjerice alergijskog rinitisa i astme, zaraznih bolesti, te raka.
The resulting mixture was extracted with diethyl ether (3×200 mL) then the organic layers were combined, washed with brine (100 mL), dried (sodium sulfate) and the solvent evaporated. 
Dobivenu smjesu ekstrahira se dietil-eterom (3 X 200 ml), organske slojeve pomiješa, ispere slanom vodom (100 ml), osuši (natrijev sulfat), a otapalo otpari.
Currently preferred insulating materials include ceramic fibers, such as glass fibers. 
Trenutno poželjni izolacijski materijali uključuju keramička vlakna, kao što su staklena vlakna.
A composition comprising a solid dispersion comprising at least 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methyl amide, its solvates, hydrates, pharmaceutically acceptable salts, or a combination thereof and a pharmaceutically acceptable matrix wherein the matrix comprises a sugar and/or sugar alcohol and/or cyclodextrin selected from the group consisting of sucrose, lactose, fructose, maltose, raffinose, sorbitol, lactitol, mannitol, maltitol, erythritol, inositol, trehalose, isomalt, inulin, maltodextrin, B-cyclodextrin, hydroxypropyl-B-cyclodextrin and sulfobutyl ether cyclodextrin. 
Pripravak koji sadrži krutu disperziju naznačen time da sadrži barem metil amid 4{4-[3-(4-kloro-3-trifluorometilfenil)-ureido]-3-fluorofenoksi}-piridin-2-karboksilne kiseline, njegove solvate, hidrate, farmaceutski prihvatljive soli, ili njihovu kombinaciju i farmaceutski prihvatljivu matricu pri čemu matrica sadrži šećer i/ili šećerni alkohol i/ili ciklodekstrin odabran iz skupine koju čine sukroza, laktoza, fruktoza, maltoza, rafinoza, sorbitol, laktitol, manitol, maltitol, eritritol, inositol, trehaloza, izomalt, inulin, maltodekstrin, B-ciklodekstrin, hidroksipropil-B-ciklodekstrin i sulfobutil eter ciklodekstrin.
The autoclave is flushed three times with nitrogen, the hydrogenation catalyst is removed from the hydrogenation mixture by filtration under pressure of nitrogen and the catalyst cake is washed with 10 ml of acetic acid. 
Autoklav se 3 x propuše dušikom, hidrogenacijski katalizator se iz hidrogenacijske smjese ukloni filtracijom pod tlakom dušika, a katalizatorski kolač ispere s 10 ml octene kiseline.
The process of claim 1, further comprising mixing a triacylglycerides-containing oil with carbon dioxide and water to form the triacylglycerides-containing oil-carbon dioxide mixture. The process of claim 1, wherein the triacylglycerides-containing oil-carbon dioxide mixture has a CO2 to triacylglycerides mass ratio in the range from about 0.001:1 to about 1:1. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da smjesa triacilglicerida i ugljičnog dioksida (12) nadalje sadržava vodik, pri čemu smjesa triacilglicerida i ugljičnog dioksida ima omjer mase vodika i triacilglicerida u rasponu od oko 0,001: 1 do oko 0,5: 1.
Example 3 relates to the method of example 1 or 2, wherein said first and said second guiding edge are determined for simultaneously contacting said dentist cutting tool at contacting points being longitudinally distanced from each other by said distance d, said guiding edges thereby defining a guiding surface along which said dentist cutting tool is to be guided. 
Postupak u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što navedeni prvi i navedeni drugi vodeći rubovi služe za istodobno stupanje u kontakt s navedenim alatom za rezanje zuba na mjestima kontakta na međusobnoj uzdužnoj udaljenosti za navedenu udaljenost d, gdje navedeni vodeći rubovi tako određuju vodeću površinu, konfiguriranu za vođenje navedenog alata za rezanje zuba.
Panel according to Claim 1, characterized in that the first detent means of the lower detent engagement point (14) has a detent depression (15a), and in that the second detent means of the lower detent engagement point (14) has a detent projection (16a) adapted to said detent depression. 
Panel u skladu s patentnim zahtjevom 1, naznačen time što prvi zaponski element na donjem mjestu međudjelovanja zapona (14) ima zaponsko udubljenje (15), te što drugi zaponski element na donjem mjestu međudjelovanja zapona (14) ima zaponsko izbočenje (164), prilagođeno za navedeno zaponsko udubljenje.
A peptide of less than 15 amino acids having cytotoxic T cell inducibility, wherein said peptide comprises an amino acid sequence in which the second amino acid from the N-terminus of the amino acid sequence of SEQ ID NO: 41, 44, 46, 48 or 78 is substituted with phenylalanine, tyrosine, methionine, or tryptophan and/or the C-terminal amino acid of the amino acid sequence of SEQ ID NO: 41, 44, 46, 48 or 78 is substituted with phenylalanine, leucine, isoleucine, tryptophan, or methionine, wherein said peptide induces a cytotoxic T cell specific to a cell expressing EphA4. 
Peptid od manje od 15 aminokiselina koji može inducirati citotoksičnu T-stanicu, naznačen time što navedeni peptid ima aminokiselinski slijed u kojem je druga aminokiselina od N-kraja u aminokiselinskom slijedu SEQ ID NO:41, 44, 46, 48 ili 78 zamijenjena fenilalaninom, tirozinom, metioninom ili triptofanom i/ili je C-terminalna aminokiselina u aminokiselinskom slijedu SEQ ID NO:41, 44, 46, 48 ili 78 zamijenjena fenilalaninom, leucinom, izoleucinom, triptofanom ili metioninom, gdje navedeni peptid inducira citotoksičnu T-stanicu specifičnu za stanicu koja eksprimira EphA4.
Mice heterozygous for a first insertion of human λ sequences (hVλ3-12-hVλ3-1 and hJλ1, FIG. 
(a) susjedne sekvence lokusa humanog lakog 2 lanca koja se proteže od VA3-12 do V23-1;
one of the structures a) to i) shown below, wherein the wavy line and the arrow line correspond to the point of attachment to core structure of formula I: 
jedne od struktura od a) do i) prikazanih u nastavku, pri čemu valovita crta i crta sa strelicom odgovaraju točki spajanja s osnovnom strukturom formule I:
According to yet another main variant of embodiment 1), the endothelin receptor antagonist will be for use in combination with radiotherapy (whereby this radiotherapy is preferably whole brain radiotherapy or stereotactic radiosurgery). 
5. Macitentan za uporabu u prevenciji ili liječenju metastaza na mozgu u skladu s patentnim zahtjevima 1 do 4, naznačen time, da je radioterapija radioterapija čitavog mozga ili stereotaktička radiokirurgija.
A particularly useful combination of compounds is TEGDMA and BisGMA, see, e.g., U.S. Pat. 
Posebno korisna kombinacija spojeva je TEGDMA i BisGMA, vidi npr. US 3,066,112. HR P20080380 T3
A compound according to claim 1, or a pharmaceutically acceptable salt thereof, which is (4-{4-[5-(benzooxazol-2-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid or a pharmaceutically acceptable salt thereof. 
5. Spoj, naznačen time, da je to (4Â«(4-[5-(6-trifluorometil-piridin-3-ilamino)-piridin-2-il]-fenil3-cikloheksil)-octena kiselina, ili njegova farmaceutski prihvatljiva sol.
In a specific embodiment, the present invention provides a liquid formulation comprising: 0.001-50 mg/ml of mature elastase protein in a solution of 137 mM sodium chloride, 2.7 mM potassium phosphate, 10 mM sodium phosphate with a pH of 7.4. 
(£) ima koncentraciju zrelog tipa I elastaze od 0,1 mg/ml - 50 mg/ml. Farmaceutski sastav prema patentnom zahtjevu 21, naznačen time da: (a) sadrži 137 mM natrij klorida, 2.7 mM kalij fosfata, 10 mM natrij fosfata, ima pH 7.4, gdje opcionalno:
adding to said water-phase vessel of step c, a buffering agent selected from a group comprising Di Sodium Hydrogen Ortho Phosphate, Sodium Hydrogen Ortho Phosphate and the like in an amount between 0.001% (w/w) to 1.00% (w/w), preferably 0.05% (w/w), more preferably 0.5% (w/w). 
dodavanje u navedenu posudu s vodenom fazom iz stupnja c puferskog agensa odabranog iz skupine koja sadrži dinatrijev hidrogenortofosfat, natrijev hidrogenortofosfat i slične, u količini između 0,001% (tež.) do 1,00% (tež.), prvenstveno 0,05% (tež.), pogodnije 0,5% (tež.),
A metal matrix syntactic foam comprising the filler of claim 7 and a metal and/or a metal alloy. 
Sintaktička pjena metalne matrice koja sadrži punilo sukladno patentnom zahtjevu 8 i metal i/ili leguru metala.
The tablet as claimed in claim 1, in which said lubricating agent is selected from the group consisting of Ca stearate, Mg stearate, sodium stearyl fumarate and stearic acid. 
Tableta prema zahtjevu 1, naznačena time, da su navedena maziva odabrana iz skupine koju čine Ca-stearat, Mg- stearat, natrijev stearilfumarat, stearinska kiselina i ostalo.
The device according to claim 1, wherein the perforated sheet is made of a metal material. 
Uređaj sukladno zahtjevu 1, gdje je perforirani list izrađen od metalnog materijala.
reaction of compound of formula (VIII) with a compound of formula (VII) to form a compound of formula (VI), 
reakcijom spoja sa formulom (VIII) sa spojem sa formulom (VII) da se dobije spoj sa formulom (VI), [image]
The method of claim 33, wherein the disease is macular degeneration, age related macular degeneration (AMD), wet AMD, dry AMD, or Geographic Atrophy. 
Spoj ili sastav za upotrebu prema zahtjevu 13, gdje je bolest: makularna degeneracija, starosna makularna degeneracija (AMD), vlažna AMD, suha AMD ili geografska atrofija;